CD
CDT.US CDT Equity Inc.
- Market cap
- USD 408K
- P/E
- -
- P/B
- 0.00x
- ROE
- 17.3%
- Dividend yield
- 1,954.60%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CDT.US undervalued?
Graham numberThe Graham number of CDT Equity Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CDT Equity Inc. fundamental analysis
No fundamental analysis for CDT Equity Inc. yet.
CDT Equity Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CDT Equity Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I cli…
Full company profileCDT Equity Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CDT Equity Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 922M | 2.72B | 2.89B |
| Gross Profit | - | - | - | -457K | 1.03B | 1.12B |
| Operating Income | -3.17M | -3.16M | -5.26M | -15.4M | -36.8M | 391M |
| EBITDA | -3.66M | -4.89M | 3.05M | -15.8M | -36.5M | 473M |
| Net Income | -3.66M | -4.89M | -535K | -17.8M | -39.2M | 239M |
| EPS | -15,264 | -3,697 | -95 | -2,464 | -11,779 | 449 |
| Balance Sheet | ||||||
| Total Assets | 213K | 5.00K | 7.22M | 4.19M | 3.54B | 3.50B |
| Total Liabilities | 193K | 10.1M | 7.68M | 11.0M | 2.28B | 2.12B |
| Shareholders' Equity | 20.6K | -10.1M | -457K | -6.79M | 1.26B | 1.38B |
| Cash & Short-term Investments | 48.6K | 346K | 4.23M | 554K | 390M | 349M |
| Total Debt | 177K | 2.01M | 985K | 7.46M | 1.29B | 1.32B |
| Cash Flow | ||||||
| Operating Cash Flow | -2.15M | -2.27M | -7.73M | -9.68M | -15.6M | 48.2M |
| Capital Expenditure | 5.00 | 0.00 | 0.00 | 51.0K | 2.40M | 170M |
| Free Cash Flow | -2.15M | -2.27M | -7.73M | -9.73M | -18.0M | -122M |
| Ratios | ||||||
| ROE | -17,736.1% | - | - | - | -3.1% | 17.3% |
| ROA | -1,715.9% | -97,740.0% | -7.4% | -424.6% | -1.1% | 6.8% |
| Net Profit Margin | - | - | - | -1.9% | -1.4% | 8.3% |
| Debt to Equity | 8.59x | - | - | - | 1.02x | 0.95x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CDT Equity Inc. dividends
- Dividend yield
- 1,954.60%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 7.97M | 2,392 | - |
| 2024 | USD 8.20M | 1,134 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Nov 6, 2026.
Who owns CDT Equity Inc.
- Insiders 17.52%
- Institutions 0.06%
- Public & others 82.42%
- Shares outstanding 1.02M
- Free float 21.0K
Top funds holding CDT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 197.00 | 2.19% | 0.00% | Aug 2026 |
Top institutions holding CDT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Financial Management Professionals Inc | 10.0K | 0.10% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 9.10K | 0.09% | +8,168.18% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
CDT Equity Inc. company profile
- Company name
- CDT Equity Inc.
- Ticker
- CDT.US
- Exchange
- USA Stocks
- Listed since
- Sep 25, 2023
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 4
- Fiscal year end
- December
- Address
- 4581 Tamiami Trail North, Naples, FL, United States, 34103
- Phone
- 646 491 9132
- Website
- cdtequity.com
About CDT Equity Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
CDT Equity Inc. management
3- Mr. James BlighCo-Founder, CEO, CFO & Director · born 1987
- Dr. Joanne M. HollandChief Scientific Officer · born 1975
- Dr. David Joszef TapolczayHead of Strategy & Licensing · born 1959